vs
Caris Life Sciences, Inc.（CAI）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是Caris Life Sciences, Inc.的1.0倍（$217.4M vs $216.8M），Caris Life Sciences, Inc.净利率更高（11.2% vs 1.4%，领先9.8%），Caris Life Sciences, Inc.同比增速更快（113.4% vs 0.5%），Caris Life Sciences, Inc.自由现金流更多（$55.3M vs $36.4M）
Caris生命科学是一家领先的精准医疗生物技术企业，专注于肿瘤领域的先进分子检测服务，为肿瘤医生提供可落地的基因组与分子层面洞察以制定个性化癌症治疗方案，同时与生物制药企业合作加速抗癌新药研发，业务覆盖北美、欧洲及亚太主要市场。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
CAI vs RPD — 直观对比
营收规模更大
RPD
是对方的1.0倍
$216.8M
营收增速更快
CAI
高出112.9%
0.5%
净利率更高
CAI
高出9.8%
1.4%
自由现金流更多
CAI
多$18.9M
$36.4M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $216.8M | $217.4M |
| 净利润 | $24.3M | $3.1M |
| 毛利率 | — | 68.9% |
| 营业利润率 | 15.1% | 1.0% |
| 净利率 | 11.2% | 1.4% |
| 营收同比 | 113.4% | 0.5% |
| 净利润同比 | 135.9% | 44.1% |
| 每股收益（稀释后） | $0.08 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAIRPD
| Q4 25 | — | $217.4M | ||
| Q3 25 | $216.8M | $218.0M | ||
| Q2 25 | $181.4M | $214.2M | ||
| Q1 25 | — | $210.3M | ||
| Q4 24 | — | $216.3M | ||
| Q3 24 | $101.6M | $214.7M | ||
| Q2 24 | $100.0M | $208.0M | ||
| Q1 24 | — | $205.1M |
净利润CAIRPD
| Q4 25 | — | $3.1M | ||
| Q3 25 | $24.3M | $9.8M | ||
| Q2 25 | $-71.8M | $8.3M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $-67.7M | $15.4M | ||
| Q2 24 | $-66.2M | $6.5M | ||
| Q1 24 | — | $1.4M |
毛利率CAIRPD
| Q4 25 | — | 68.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.6% | ||
| Q1 25 | — | 71.7% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 70.7% | ||
| Q1 24 | — | 70.3% |
营业利润率CAIRPD
| Q4 25 | — | 1.0% | ||
| Q3 25 | 15.1% | 2.7% | ||
| Q2 25 | -9.9% | 1.6% | ||
| Q1 25 | — | -0.0% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | -59.9% | 6.0% | ||
| Q2 24 | -67.0% | 2.5% | ||
| Q1 24 | — | 4.7% |
净利率CAIRPD
| Q4 25 | — | 1.4% | ||
| Q3 25 | 11.2% | 4.5% | ||
| Q2 25 | -39.6% | 3.9% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | -66.6% | 7.2% | ||
| Q2 24 | -66.2% | 3.1% | ||
| Q1 24 | — | 0.7% |
每股收益（稀释后）CAIRPD
| Q4 25 | — | $0.05 | ||
| Q3 25 | $0.08 | $0.15 | ||
| Q2 25 | $-7.97 | $0.13 | ||
| Q1 25 | — | $0.03 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | $-2.59 | $0.21 | ||
| Q2 24 | $-2.54 | $0.09 | ||
| Q1 24 | — | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $755.5M | $474.7M |
| 总债务越低越好 | $375.9M | — |
| 股东权益账面价值 | $478.4M | $154.7M |
| 总资产 | $984.6M | $1.7B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资CAIRPD
| Q4 25 | — | $474.7M | ||
| Q3 25 | $755.5M | $407.1M | ||
| Q2 25 | $721.2M | $511.7M | ||
| Q1 25 | — | $493.5M | ||
| Q4 24 | — | $521.7M | ||
| Q3 24 | — | $443.7M | ||
| Q2 24 | — | $442.6M | ||
| Q1 24 | — | $411.7M |
总债务CAIRPD
| Q4 25 | — | — | ||
| Q3 25 | $375.9M | — | ||
| Q2 25 | $373.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CAIRPD
| Q4 25 | — | $154.7M | ||
| Q3 25 | $478.4M | $127.2M | ||
| Q2 25 | $452.9M | $90.4M | ||
| Q1 25 | — | $52.7M | ||
| Q4 24 | — | $17.7M | ||
| Q3 24 | $-2.4B | $-5.1M | ||
| Q2 24 | $-2.4B | $-52.6M | ||
| Q1 24 | — | $-86.4M |
总资产CAIRPD
| Q4 25 | — | $1.7B | ||
| Q3 25 | $984.6M | $1.7B | ||
| Q2 25 | $955.1M | $1.6B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
负债/权益比CAIRPD
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.4M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $55.3M | $36.4M |
| 自由现金流率自由现金流/营收 | 25.5% | 16.8% |
| 资本支出强度资本支出/营收 | 3.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.57× | 12.01× |
| 过去12个月自由现金流最近4个季度 | — | $146.2M |
8季度趋势，按日历期对齐
经营现金流CAIRPD
| Q4 25 | — | $37.6M | ||
| Q3 25 | $62.4M | $39.0M | ||
| Q2 25 | — | $47.5M | ||
| Q1 25 | — | $29.8M | ||
| Q4 24 | — | $63.8M | ||
| Q3 24 | — | $44.0M | ||
| Q2 24 | — | $32.9M | ||
| Q1 24 | — | $31.1M |
自由现金流CAIRPD
| Q4 25 | — | $36.4M | ||
| Q3 25 | $55.3M | $34.8M | ||
| Q2 25 | — | $46.6M | ||
| Q1 25 | — | $28.4M | ||
| Q4 24 | — | $62.6M | ||
| Q3 24 | — | $42.6M | ||
| Q2 24 | — | $32.6M | ||
| Q1 24 | — | $30.4M |
自由现金流率CAIRPD
| Q4 25 | — | 16.8% | ||
| Q3 25 | 25.5% | 16.0% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 13.5% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 19.9% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 14.8% |
资本支出强度CAIRPD
| Q4 25 | — | 0.5% | ||
| Q3 25 | 3.3% | 1.9% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.3% |
现金转化率CAIRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | 2.57× | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAI
| Molecular Profiling Services | $207.6M | 96% |
| Pharma Research And Development Services | $9.2M | 4% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
